Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma

Exposure to a Histone Deacetylase Inhibitor Has Detrimental Effects on Human Lymphocyte Viability and Function

(2014) D. J. L. Wong et al.   Cancer Immunology Research

Trametinib (GSK1120212) in the treatment of melanoma

(2013) April KS Salama et al.   EXPERT OPINION ON PHARMACOTHERAPY

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

(2013) Paolo A Ascierto et al.   LANCET ONCOLOGY

Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo

(2013) C. Posch et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

BRAF(V600) Inhibitor GSK2118436 Targeted Inhibition of Mutant BRAF in Cancer Patients Does Not Impair Overall Immune Competency

(2012) D. S. Hong et al.   CLINICAL CANCER RESEARCH

Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines

(2012) Erika von Euw et al.   Molecular Cancer

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

NRAS mutant melanoma: biological behavior and future strategies for therapeutic management

(2012) I V Fedorenko et al.   ONCOGENE

MAP kinase signaling and inhibition in melanoma

(2012) R J Sullivan et al.   ONCOGENE

NRAS mutation status is an independent prognostic factor in metastatic melanoma

(2011) John A. Jakob et al.   CANCER

Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway

(2011) Mohammad Atefi et al.   PLoS One

Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

(2010) J. R. Dry et al.   CANCER RESEARCH

Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

(2010) Sonja J. Heidorn et al.   CELL

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

(2010) Gideon Bollag et al.   NATURE

The MAPK pathway in melanoma

(2009) Leslie A Fecher et al.   CURRENT OPINION IN ONCOLOGY

Selective Inhibitors of the Mutant B-Raf Pathway: Discovery of a Potent and Orally Bioavailable Aminoisoquinoline

(2009) Adrian L. Smith et al.   JOURNAL OF MEDICINAL CHEMISTRY

Combined Targeting of BRAF and CRAF or BRAF and PI3K Effector Pathways Is Required for Efficacy in NRAS Mutant Tumors

(2009) Bijay S. Jaiswal et al.   PLoS One

V600EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway

(2009) C. A. Pratilas et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas

(2008) K. S.M. Smalley et al.   MOLECULAR CANCER THERAPEUTICS

CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations

(2008) K S M Smalley et al.   ONCOGENE

Oncogenic BRAFV600E inhibits BIM expression to promote melanoma cell survival

(2008) Robert A. Cartlidge et al.   Pigment Cell & Melanoma Research

GSK-3β regulates cyclin D1 expression: A new target for chemotherapy

(2007) Fumi Takahashi-Yanaga et al.   CELLULAR SIGNALLING